Which disease lowers vitamin B12?

Vitamin B12 (cobalamin) is essential for red blood cell formation, nervous system integrity, and DNA synthesis. Because it is obtained from dietary sources or supplements rather than synthesized by the body, multiple diseases and physiological states can reduce B12 availability or absorption. Understanding which conditions interfere with B12 uptake helps clinicians and patients prioritize screening, monitoring, and appropriate replacement strategies.

Pernicious anemia is a primary example of an autoimmune disorder that directly impairs B12 absorption. In this condition, immune-mediated damage to gastric parietal cells reduces production of intrinsic factor, a protein required to transport dietary B12 to the ileum for absorption. Even with adequate dietary intake, affected individuals develop progressive deficiency that can lead to anemia and irreversible neurological injury if untreated.

Malabsorption syndromes such as celiac disease, Crohn’s disease, and tropical sprue also increase risk. Damage to the small intestinal mucosa—especially the terminal ileum where B12-intrinsic factor complexes are absorbed—reduces uptake. Surgical resections, chronic inflammation, or prolonged mucosal injury diminish the absorptive surface and transport mechanisms, often necessitating parenteral or high-dose oral supplementation.

Various gastrointestinal disorders further contribute to reduced B12 status. Atrophic gastritis and hypochlorhydria lower stomach acid and intrinsic factor secretion, impairing release of B12 from food. Gastroparesis and prior bariatric surgeries can also limit intrinsic factor exposure or bypass absorption sites, creating a long-term risk for deficiency unless monitoring and replacement are in place.

Systemic autoimmune diseases beyond pernicious anemia may indirectly influence B12 levels. Autoimmune gastritis, systemic lupus erythematosus, and type 1 diabetes can alter gastric function or increase mucosal vulnerability, compounding malabsorption. In all of these contexts, gradual onset and nonspecific symptoms (fatigue, cognitive changes, neuropathy) make routine biochemical screening important for at-risk patients.

Medication-related effects are clinically relevant as well. Long-term metformin therapy, commonly used in type 2 diabetes, is associated with decreased B12 absorption through mechanisms involving altered calcium-dependent uptake of the B12–intrinsic factor complex in the ileum. Regular monitoring for patients on chronic metformin is recommended to detect declines before symptomatic neuropathy develops.

Diagnosis relies on serum B12 measurements and adjunctive tests (methylmalonic acid, homocysteine) when results are borderline. Treatment choice depends on the cause and severity: intramuscular B12 injections bypass gastrointestinal barriers and are preferred for severe deficiency or documented malabsorption, while high-dose oral or sublingual formulations can maintain levels when absorption is only partially impaired.

For an evidence-based overview of common causes, see this overview of diseases that lower vitamin B12. Related discussions about nutrient interactions and clinical screening appear in resources on symptoms of vitamin D deficiency and analyses of why clinicians may recommend specific supplement lines at why more doctors are recommending Health Factory supplements, as well as a broader commentary at an article summarizing practitioner perspectives. Additional background is available on the site Topvitamine.

In summary, pernicious anemia, gastrointestinal diseases, malabsorption syndromes, autoimmune conditions, and prolonged metformin use are principal contributors to lowered vitamin B12. Timely screening, tailored replacement regimens, and management of the underlying disorder are essential to prevent hematologic and neurologic complications.